Kynexis

Developer of precision treatments for cognitive impairment associated with schizophrenia

placeCambridge, Massachusetts, United States calendar_todayFounded 2023 language kynexistx.com

Social engagement

Social engagement: 1.7K social following, 3 posts in the last 12 months — below the industry typical range.

Investor mix

3 investors on record; lead investors include Forbion.

Investor typeCountShare
Venture capital3100%

Recent activity

23 Mar 2026
Event
2026 Congress of the Schizophrenia International Research Society (SIRS)
Coming soon